U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.					
r form 1449A/PTO	Application Number	10/742,346			
	Confirmation No.	6421			
ORMATION DISCLOSURE	Filing Date	December 19, 2003 Robert Falotico 1615			
ATEMENT BY APPLICANT	First Named Inventor				
	Group Art Unit				
(use as many sheets as necessary)	Examiner Name	Caralynne Helm			
Sheet 1 of 2	Attorney Docket Number	CRD5062USNP			

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite		id Code <sup>2</sup> f known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		6,153,252	Α	Hossainy, et al.	11-28-2000	

## FOREIGN PATENT DOCUMENTS

	Cite	Foreign Patent Document		nt	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials		Office <sup>3</sup>	Number <sup>4</sup> Kir	ndCode <sup>5</sup>	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T <sup>6</sup>

Examiner	(0 1 11 1	Date	VE IUU IUU I
Signature	/Caralynne Helm/	Considered	05/06/2010

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

The second secon					
Application Number	10/742,346				
Confirmation No.	6421				
Filing Date	December 19, 2003				
First Named Inventor	Robert Falotico				
Group Art Unit	1615				
Examiner Name	Caralynne Helm				
Attorney Docket Number	CRD5062USNP				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	$T^2$
	.,,,,,	<b>AJROLDI</b> , G, et al. "Fluoroelastomers-Dependence of Relaxation Phenomena on Composition", Polymer, Volume 30 (1989) pp. 2180-2187	
		<b>CAMPBELL</b> , G., et al. "Phenotypic Modulation of Smooth Muscle Cells in Primary Culture", Table of Contents, Chapter 4, Volume 1, p. 39 (1985)	
		CLOWES and CLOWES, "Kinetics of Cellular Proliferation After Arterial Injury", Laboratory Investigation, Vol. 52, No. 6 (1985) pp. 611-616	
		<b>DEROANNE</b> , C., et al. "Histone Deacetylases Inhibitors as Anti-Angiogenic Agents Altering Vascular Endothelial Growth Factor Signaling", Oncogene, Volume 21 (2002) pp. 427-436	
		<b>LANG</b> , R., et al. "Effects of Okadaic Acid and ATPγS on Cell Length and Ca <sup>2+</sup> - Channel Currents Recorded in Single Smooth Muscle Cells of the Guinea-Pig Taenia Caeci", British Journal of Pharmacology, Vol. 104 (1991) pp. 331-336	
		<b>MINTZ</b> , G., et al. "Intravascular Ultrasound Predictors of Restenosis After Percutaneous Transcatheter Coronary Revascularization", JACC, Vol. 27, No. 7 (1996) pp. 1678-1687	
		MINTZ, G., et al. "Arterial Remodeling After Coronary Angioplasty: A Serial Intravascular Ultrasound Study", Circulation, Volume 94(1) (1996) pp. 35-43	
		SERRUYS, P., et al. "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study", Clinical Investigations and Reports, Volume 93(3) (1996) pp. 412-422	
		<b>WOO</b> , S., et al. "Structurally simple Trichostatin a-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors", J. Medical Chemistry, Volume 45 (2002) pp. 2877-2885	

		Examiner Signature	/Caralyr	nne Helm/	Date Considered	05/06/2010
--	--	-----------------------	----------	-----------	--------------------	------------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.